Firstly, we measured the proliferative capability of tumor cells by CCK-8 assays. The Talazoparib in vitro proliferation of HCC cells was significantly retarded by KPNA2 inhibition (Figure 2a) and accelerated by KPNA2 overexpression (Figure 2b). It is noteworthy that PLAG1 inhibition could significantly counterweighed the VS-4718 chemical structure effect of KPNA2 overexpression in Huh7 cells (Figure 2b). Evidences have revealed the involvement of IGF-II in metastasis of HCC cells [19,20]; we then sought to determine whether

KPNA2 could promote the metastasis of HCC cells through PLAG1. Transwell assay was applied to find that inhibition of KPNA2 lead to decrease of migratory cells by nearly 40-50% in SMMC7721 cell lines (Figure 2c). KPNA2 over-expression could remarkably increase the migratory ability of Huh7 HCC cells in vitro and PLAG1 knock-down could significantly offset the effect of KPNA2 over-expression in HCC cell metastasis (Figure 2d). Collectively, the results indicated that the role of KPNA2 in proliferation and migration relied on PLAG1. Figure 2 PLAG1 is essential for the role of KPNA2 in proliferation and invasion of tumor cells. (a-b) The cell proliferation of HCC cells was assayed every 12

hours for two days in three independent experiments. ★ represents statistical AUY-922 cost significance compared to Scramble or GFP cells. (c-d) The number of migratory HCC cells was calculated with crystal violet staining and representative fields were exhibited. Bar graphs in left panel show mean the average count of six random microscopic fields and the mean SEM. ★ represents statistical significance. The co-enrichment of nucleus PLAG1 and KPNA2 in vivo To determine the in vivo interaction and clinical significance of KPNA2 and PLAG1, we performed an immunohistochemical Phosphoglycerate kinase analysis of KPNA2 and PLAG1 in a tissue microarray including 314 HCC patients with tumoral (T) and corresponding non-tumoral (NT) in separate section (Table 1). Based on nucleus enrichment in cells of tumoral (T) and non-tumoral (NT) tissues, we defined the contents

of KPNA2 and PLAG1 as positive or negative (Figure 3) and subdivided all patients into these groups: KnPn (NN = 117, NNT = 235), negative KPNA2 and negative PLAG1 enrichment in nucleus; KnPp (NN = 45, NNT = 68), negative KPNA2 and high PLAG1 enrichment in nucleus; KpPn (NN = 54, NNT = 2) positive KPNA2 and negative PLAG1 enrichment in nucleus; KpPp (NN = 98, NNT = 9), positive KPNA2 and positive PLAG1 enrichment in nucleus (Figure 3). Consistent with previous report [12], the positive KPNA2 expression was almost tumor specific, as only non-tumoral tissues of 11 HCC patients showed positive KPNA2 expression. Besides, the positive nucleus staining of PLAG1 in tumors was more frequent than in non-tumoral tissues (Table 2), further supporting the role of PLAG1 in HCC.